Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial

NCT07153471 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07153471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07153471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 15, 2025
Completion date
May 31, 2028
Enrollment
800 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis